Big data brings big challenges, big opportunities

SAN DIEGO – At the State of Innovation session during BIO 2017, a brief exchange neatly summed up the current status of big data. Noting that clinical trial expenses and success rates have not changed appreciably as the amount of data that is collected from patients, most prominently but not only through genome sequencing, has increased, venture capital firm Flagship Pioneering’s Jeremy Springhorn lamented that “there’s all this information out there, yet we’re not using it.”

Richard Harrison, chief scientific officer of Clarivate Analytics (parent company of BioWorld), disagreed, noting that he and colleagues have published data that show a strong increase in the use of biomarkers in clinical trials. “We’re using it,” Harrison said of the information that the life sciences industry is awash in. “I just don’t know if we’re using it correctly.”

Author: Anette Breindl


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s